アメリカ合衆国 - 英語 - NLM (National Library of Medicine)

avkare - dofetilide (unii: r4z9x1n2nd) (dofetilide - unii:r4z9x1n2nd) - dofetilide capsules are indicated for the maintenance of normal sinus rhythm (delay in time to recurrence of atrial fibrillation/atrial flutter [af/afl]) in patients with atrial fibrillation/atrial flutter of greater than one week duration who have been converted to normal sinus rhythm. because dofetilide can cause life threatening ventricular arrhythmias, it should be reserved for patients in whom atrial fibrillation/atrial flutter is highly symptomatic. in general, antiarrhythmic therapy for atrial fibrillation/atrial flutter aims to prolong the time in normal sinus rhythm. recurrence is expected in some patients (see clinical studies ). dofetilide capsules are indicated for the conversion of atrial fibrillation and atrial flutter to normal sinus rhythm. dofetilide capsules have not been shown to be effective in patients with paroxysmal atrial fibrillation. dofetilide is contraindicated in patients with congenital or acquired long qt syndromes. dofetilide should not be used in patients with a baseline qt interval or qtc >440 msec (500 msec in patients with ventricular conduction abnormalities). dofetilide is also contraindicated in patients with severe renal impairment (calculated creatinine clearance <20 ml/min). the concomitant use of verapamil or the cation transport system inhibitors cimetidine, trimethoprim (alone or in combination with sulfamethoxazole), or ketoconazole with dofetilide is contraindicated (see warnings and precautions, drug-drug interactions ), as each of these drugs cause a substantial increase in dofetilide plasma concentrations. in addition, other known inhibitors of the renal cation transport system such as prochlorperazine, dolutegravir and megestrol should not be used in patients on dofetilide. the concomitant use of hydrochlorothiazide (alone or in combinations such as with triamterene) with dofetilide is contraindicated (see precautions, drug-drug interactions ) because this has been shown to significantly increase dofetilide plasma concentrations and qt interval prolongation. dofetilide is also contraindicated in patients with a known hypersensitivity to the drug.

アメリカ合衆国 - 英語 - NLM (National Library of Medicine)

aurobindo pharma limited - dofetilide (unii: r4z9x1n2nd) (dofetilide - unii:r4z9x1n2nd) - maintenance of normal sinus rhythm (delay in af/afl recurrence) dofetilide capsules are indicated for the maintenance of normal sinus rhythm (delay in time to recurrence of atrial fibrillation/atrial flutter [af/afl]) in patients with atrial fibrillation/atrial flutter of greater than one week duration who have been converted to normal sinus rhythm. because dofetilide capsules can cause life threatening ventricular arrhythmias, it should be reserved for patients in whom atrial fibrillation/atrial flutter is highly symptomatic. in general, antiarrhythmic therapy for atrial fibrillation/atrial flutter aims to prolong the time in normal sinus rhythm. recurrence is expected in some patients (see clinical studies ). conversion of atrial fibrillation/flutter dofetilide capsules are indicated for the conversion of atrial fibrillation and atrial flutter to normal sinus rhythm. dofetilide capsules have not been shown to be effective in patients with paroxysmal atrial fibrillation. dofetilide capsules are contraindicated in patients with congenital or acquired long qt syndromes. dofetilide capsules should not be used in patients with a baseline qt interval or qtc >440 msec (500 msec in patients with ventricular conduction abnormalities). dofetilide capsules are also contraindicated in patients with severe renal impairment (calculated creatinine clearance <20 ml/min). the concomitant use of verapamil or the cation transport system inhibitors cimetidine, trimethoprim (alone or in combination with sulfamethoxazole), or ketoconazole with dofetilide capsules are  contraindicated (see warnings and precautions, drug-drug interactions ), as each of these drugs cause a substantial increase in dofetilide plasma concentrations. in addition, other known inhibitors of the renal cation transport system such as prochlorperazine, dolutegravir and megestrol should not be used in patients on dofetilide capsules. the concomitant use of hydrochlorothiazide (alone or in combinations such as with triamterene) with dofetilide capsules are contraindicated (see precautions, drug-drug interactions ) because this has been shown to significantly increase dofetilide plasma concentrations and qt interval prolongation. dofetilide capsules are also contraindicated in patients with a known hypersensitivity to the drug.

カナダ - 英語 - Health Canada

jamp pharma corporation - efavirenz - tablet - 600mg - efavirenz 600mg - nonnucleoside reverse transcriptase inhibitors

アメリカ合衆国 - 英語 - NLM (National Library of Medicine)

accord healthcare, inc. - dofetilide (unii: r4z9x1n2nd) (dofetilide - unii:r4z9x1n2nd) - dofetilide capsules are indicated for the maintenance of normal sinus rhythm (delay in time to recurrence of atrial fibrillation/atrial flutter [af/afl]) in patients with atrial fibrillation/atrial flutter of greater than one week duration who have been converted to normal sinus rhythm. because dofetilide can cause life threatening ventricular arrhythmias, it should be reserved for patients in whom atrial fibrillation/atrial flutter is highly symptomatic. in general, antiarrhythmic therapy for atrial fibrillation/atrial flutter aims to prolong the time in normal sinus rhythm. recurrence is expected in some patients (see clinical studies ). dofetilide capsules are indicated for the conversion of atrial fibrillation and atrial flutter to normal sinus rhythm. dofetilide capsules has not been shown to be effective in patients with paroxysmal atrial fibrillation. dofetilide is contraindicated in patients with congenital or acquired long qt syndromes. dofetilide should not be used in p

オーストラリア - 英語 - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - valsartan, quantity: 51.4 mg; sacubitril, quantity: 48.6 mg - tablet, film coated - excipient ingredients: hyprolose; sodium starch glycollate type a; colloidal anhydrous silica; microcrystalline cellulose; purified talc; magnesium stearate; titanium dioxide; hypromellose; iron oxide yellow; macrogol 4000 - pharmacor sacubitril/valsartan is indicated in adult patients for the treatment of chronic heart failure (nyha class ii-iv) with reduced ejection fraction.

オーストラリア - 英語 - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - sacubitril, quantity: 97.2 mg; valsartan, quantity: 102.8 mg - tablet, film coated - excipient ingredients: hyprolose; purified talc; microcrystalline cellulose; colloidal anhydrous silica; sodium starch glycollate type a; magnesium stearate; titanium dioxide; hypromellose; iron oxide yellow; iron oxide red; macrogol 4000; iron oxide black - pharmacor sacubitril/valsartan is indicated in adult patients for the treatment of chronic heart failure (nyha class ii-iv) with reduced ejection fraction.

オーストラリア - 英語 - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - sacubitril, quantity: 97.2 mg; valsartan, quantity: 102.8 mg - tablet, film coated - excipient ingredients: sodium starch glycollate type a; hyprolose; magnesium stearate; purified talc; microcrystalline cellulose; colloidal anhydrous silica; titanium dioxide; hypromellose; iron oxide yellow; iron oxide red; macrogol 4000; iron oxide black - valtresto is indicated in adult patients for the treatment of chronic heart failure (nyha class ii-iv) with reduced ejection fraction.

オーストラリア - 英語 - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - sacubitril, quantity: 48.6 mg; valsartan, quantity: 51.4 mg - tablet, film coated - excipient ingredients: sodium starch glycollate type a; hyprolose; colloidal anhydrous silica; magnesium stearate; microcrystalline cellulose; purified talc; titanium dioxide; hypromellose; iron oxide yellow; macrogol 4000 - valtresto is indicated in adult patients for the treatment of chronic heart failure (nyha class ii-iv) with reduced ejection fraction.

オーストラリア - 英語 - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - sacubitril, quantity: 24.3 mg; valsartan, quantity: 25.7 mg - tablet, film coated - excipient ingredients: sodium starch glycollate type a; microcrystalline cellulose; magnesium stearate; purified talc; colloidal anhydrous silica; hyprolose; titanium dioxide; hypromellose; iron oxide yellow; iron oxide red; macrogol 4000; iron oxide black - pharmacor sacubitril/valsartan is indicated in adult patients for the treatment of chronic heart failure (nyha class ii-iv) with reduced ejection fraction.

オーストラリア - 英語 - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - sacubitril, quantity: 24.3 mg; valsartan, quantity: 25.7 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; purified talc; colloidal anhydrous silica; sodium starch glycollate type a; magnesium stearate; hyprolose; titanium dioxide; hypromellose; iron oxide yellow; iron oxide red; macrogol 4000; iron oxide black - valtresto is indicated in adult patients for the treatment of chronic heart failure (nyha class ii-iv) with reduced ejection fraction.